Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy is ending. Now the Danish drugmaker is ...

On TikTok, where the 31-year-old mother of three chronicled her weight loss journey, commenters speculated that she was using Ozempic or another weight loss drug. “It put a bad taste in my mouth. My ...

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

As revenues fall in diabetes treatments, has the industry found a new revenue driver in weight-loss treatments ... the FDA for type 2 diabetes in May 2022, and, ahead of any additional approval ...

The latest glucagon-like peptide 1 (GLP-1) receptor agonists have been heralded for their potential to not only boost weight loss and glucose ... tirzepatide, and new GLP-1 drugs in the research ...

And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was ...

More research and development will likely improve the safety and efficacy of GLP-1-based drug therapies. New and better weight loss compounds may be discovered. But in the meantime, we need to ...

Nearly 2 in 3 people who sought to lose weight quit popular weight loss and diabetes drugs such as Ozempic or Victoza within one year, according to a new study ... until 2022 and Zepbpund for ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Weight loss drugs catapulted many into a new wellness era, and gave hope to those with diabetes, obesity and who struggled to lose weight. The global anti-obesity drugs market — including the ...